This trial, conducted by a Brazilian university, aimed to evaluate the effect of vitamin D3 on immune cells and the decline of beta cell function in new-onset type 1 diabetes for 18 months. 38 new-onset type 1 diabetes patients were randomly assigned to receive either oral vitamin D3 (2000 IU = 50µg) or a placebo daily. Inflammatory and anti-inflammatory parameters and long-term glucose levels (HbA1c) were measured. In summary, the results showed that vitamin D3 used as adjunctive therapy with insulin is safe and associated with a protective immunological effect. Moreover, this treatment was shown to slow the decline of beta cell function in patients with new-onset type 1 diabetes. More details can be found in the study.


Gabbay et al.


Link to article >>